Jade Biosciences (NASDAQ:JBIO) Upgraded to “Strong-Buy” at Lifesci Capital

Jade Biosciences (NASDAQ:JBIO) was upgraded by investment analysts at Lifesci Capital to a “strong-buy” rating in a note issued to investors on Friday,Zacks.com reports.

A number of other research analysts have also issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jade Biosciences in a report on Monday, December 29th. Guggenheim raised their target price on shares of Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Stifel Nicolaus set a $40.00 target price on shares of Jade Biosciences in a research note on Friday. Wall Street Zen raised Jade Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright began coverage on shares of Jade Biosciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $25.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.00.

Jade Biosciences Price Performance

Jade Biosciences stock opened at $14.05 on Friday. The stock’s fifty day moving average is $14.78 and its two-hundred day moving average is $11.89. The stock has a market cap of $692.81 million, a PE ratio of -1.26 and a beta of 1.03. Jade Biosciences has a 1-year low of $6.57 and a 1-year high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC bought a new stake in shares of Jade Biosciences in the second quarter worth $6,759,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Jade Biosciences during the second quarter worth about $71,000. Intech Investment Management LLC bought a new stake in shares of Jade Biosciences during the second quarter valued at approximately $230,000. Versant Venture Management LLC bought a new position in shares of Jade Biosciences in the second quarter valued at approximately $15,243,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Jade Biosciences during the 2nd quarter valued at $154,000.

About Jade Biosciences

Jade Biosciences, Inc is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small?molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.